Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients.

Ting-Ting ChungKuang-Hui YuChang Fu KuoShue-Fen LuoMeng-Jiun ChiouWen-Ching LanJung-Sheng ChenWen-Yi TsengAo-Ho HsiehLian-Chin Wang

Published in: Arthritis research & therapy (2019)

CKD progression and recovery are common in gout patients using ULDs. Febuxostat and benzbromarone were associated with a similar risk of CKD progression with allopurinol, which has a poorer recovery compared with other ULDs.

Keyphrases

chronic kidney disease
end stage renal disease
newly diagnosed
metabolic syndrome
uric acid
patient reported outcomes
patient reported